However, a phase I study combining dacomitinib (a pan-HER inhibitor) with crizotinib (a small-molecule kinase inhibitor of MET and other RTKs) in advanced NSCLC patients showed limited success due to toxicity and modest tumor response [151]. The gene discussed is MET; the disease is neoplasm.